Claims that ENDUROX™ enhances performance by altering metabolic responses to exercise were tested. In a double-blind crossover design, 10 male subjects were randomly assigned to consume 400 mg of placebo or 800 mg ENDUROX™ for 7 days. Cycle ergometry was performed for 30 minutes at 25%, followed by 10 min at 65% of peak oxygen consumption. After a 1-week washout period, subjects performed the identical exercise protocol following 7 days of reciprocal supplemental conditions. Expired gases were collected and analyzed continuously for oxygen consumption, minute ventilation, and respiratory exchange ratio. Heart rate, blood pressure, rating of perceived exertion, blood lactate, and serum glycerol data were also collected at regular intervals. A two-way ANOVA with repeated measures revealed no significant main or interaction effects involving group differences (p > 0.05) between trials for any variable during rest, 25% or 65% (VO2 peak), or recovery. Our findings do not support the ergogenic claims for ENDUROX™.
The authors are with the Department of Nutrition, Food, and Exercise Sciences, Florida State University, 001 Sandels Bldg., Tallahassee, FL 32306